Amphastar Pharmaceuticals Inc., a biopharmaceutical company specializing in complex generic and proprietary products, has entered into an exclusive licensing agreement with Nanjing Anji Biotechnology Co., Ltd. This collaboration aims to develop, manufacture, and commercialize three proprietary peptides for oncology and ophthalmology applications in the United States and Canada. The agreement, which aligns with Amphastar's mission to introduce novel and innovative therapies, can be extended for an additional ten years or until the relevant patents expire. Dr. Jack Zhang, Amphastar's CEO, highlighted that this partnership significantly enhances their pipeline with potentially best-in-class assets, reinforcing their commitment to transformative patient therapies. Anji will also receive a non-exclusive license to develop and commercialize the products outside the specified territories.